ADMA

Kestenberg-Messina Kaitlin M.

Known title: COO and SVP, ComplianceCIK: 0002017423

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

ADMA Biologics Draws Investor Attention Amid Market Decline. Recent reports indicate that ADMA Biologics is attracting investor attention and showing relative strength while the broader market declines. Analysts have expressed optimism, with an average price target of $17.00, which is well above the current trading range. This suggests that some market participants view the stock as undervalued relative to its long-term potential, despite recent volatility.

this person other insiders at ADMA

Transaction History

ADMA▼ Sell$27K
ADMA▼ Sell$185K
ADMA▲ Buy$13K
ADMA▲ Buy$5K
ADMA▲ Buy$7K
ADMA▲ Buy$4K
ADMA▲ Buy$3K
ADMA▼ Sell$158K
ADMA▼ Sell$0
ADMA▼ Sell$65K
ADMA▼ Sell$155K
ADMA▼ Sell$133K
ADMA▲ Buy$0
ADMA▲ Buy$22K
ADMA▼ Sell$22K
ADMA▼ Sell$52K
ADMA▼ Sell$367K
ADMA▼ Sell$67K
ADMA▼ Sell$150K
ADMA▼ Sell$29K
ADMA▲ Buy$0
ADMA▲ Buy$54K
ADMA▼ Sell$54K
ADMA▼ Sell$32K
ADMA▼ Sell$53K
ADMA▲ Buy$19K
ADMA▲ Buy$11K
ADMA▲ Buy$40K
ADMA▲ Buy$24K
ADMA▼ Sell$408K
ADMA▼ Sell$34K
ADMA▼ Sell$23K
ADMA▲ Buy$0
ADMA▼ Sell$14K

We use analytics to understand how market-wall is used. No personal data is sold.